
Fierce Pharma Asia—China biotech deal boom; Takeda's narcolepsy win; Sino Biopharm's LaNova buyout
Biotech deals involving assets developed in China are surging, a Jefferies report shows. Takeda is preparing its narcolepsy candidate oveporexton for an FDA filing after two positive phase 3 readouts. Merck & Co.'s PD-1xVEGF partner is being …